-
-
To comply with
amendments to COMAR 10.09.03.07 H(3), prescribers are required to
-
complete a
DHMH Medwatch form. A copy of the form must be forwarded to the
Maryland
-
Pharmacy
Program for its review and approval before the Program will
reimburse at the brand
-
rate for
prescriptions dispensed as “Brand Medically Necessary”.
-
-
DHMH will send
all approved forms to U.S. Food and Drug Administration (FDA) as
official
-
reports of
adverse events or product problems regarding generic drug
products. The FDA may
-
choose further
investigate the incident and seek documentation of the adverse
drug reaction
-
(ADR) or
otherwise substantiate the circumstances and veracity of the ADR
complaint.
-
Adverse events
are defined as life threatening, disabling, impairing, or damaging
situations
-
and/or the
involvement of a hospital stay. Product problems are defined as
an allergic reaction
-
to an allergen
present in the generic product that is not included in the brand
name product or
-
a therapeutic
failure of the generic product when plasma levels are below
efficacious published
-
pharmacokinetic profiles for the brand name product.
-
-
To request an
over-ride for a “brand medically necessary” prescription, the
prescriber must
-
complete and
sign the DHMH Medwatch form and fax a copy to the Maryland
Pharmacy
-
Program at
410-333-5398. Mere submission of the form is no guarantee that
the request will
-
be honored.
The prescriber should write “MEDWATCH FORM SUBMITTED” in addition
to
-
“BRAND
MEDICALLY NECESSARY” on the prescription order to indicate to the
dispensing
-
pharmacist
that the necessary documentation has been submitted. If a generic
version of
-
the drug made
by a different manufacturer is available, the Program may require
a trial with the
-
other generic
drug before approving the brand name product. A copy of a DHMH
Medwatch
-
form and
instructions are available at the links below.